Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328131185> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4328131185 abstract "Purpose Phosphoinositide 3-kinase (PI3K) inhibition is used for the treatment of certain cancers, but can cause profound hyperglycemia and insulin resistance, for which sodium-glucose cotransporter-2 (SGLT2) inhibitors have been proposed as a preferred therapy. The objective of this research is to assess the effectiveness and safety of SGLT2 inhibitors for hyperglycemia in PI3K inhibition. Methods We conducted a single-center retrospective review of adults initiating the PI3k inhibitor alpelisib. Exposure to different antidiabetic drugs and adverse events including diabetic ketoacidosis (DKA) were assessed through chart review. Plasma and point-of-care blood glucoses were extracted from the electronic medical record. Change in serum glucose and the rate of DKA on SGLT2 inhibitor versus other antidiabetic drugs were examined as co-primary outcomes. Results We identified 103 patients meeting eligibility criteria with median follow-up of 85 days after starting alpelisib. When SGLT2 inhibitors were used to treat hyperglycemia, they were associated with a decrease in mean random glucose by -54 mg/dL (95% CI -99 to -8) in adjusted linear modeling. Five cases of DKA were identified, two occurring in patients on alpelisib plus SGLT2 inhibitor. Estimated incidence of DKA was: alpelisib plus SGLT2 inhibitor, 24 DKA cases per 100 patient-years (95% CI 6, 80); alpelisib with non-SGLT2 inhibitor antidiabetic drugs, 7 (95% CI 0.1, 34); alpelisib only, 4 (95% CI 0.1, 21). Conclusions SGLT2 inhibitors are effective treatments for hyperglycemia in the setting of PI3K inhibition, but given possible adverse events, SGLT2 inhibitors should be used with caution." @default.
- W4328131185 created "2023-03-22" @default.
- W4328131185 creator A5000623233 @default.
- W4328131185 creator A5003136757 @default.
- W4328131185 creator A5009492679 @default.
- W4328131185 creator A5013685119 @default.
- W4328131185 creator A5027611546 @default.
- W4328131185 date "2023-03-21" @default.
- W4328131185 modified "2023-09-27" @default.
- W4328131185 title "Sodium-Glucose Cotransporter-2 Inhibitors for Hyperglycemia in Phosphoinositide 3-kinase Pathway Inhibition" @default.
- W4328131185 cites W2162693177 @default.
- W4328131185 cites W2588103555 @default.
- W4328131185 cites W2746031332 @default.
- W4328131185 cites W2765901725 @default.
- W4328131185 cites W2786945112 @default.
- W4328131185 cites W2809999132 @default.
- W4328131185 cites W2896744886 @default.
- W4328131185 cites W2901442091 @default.
- W4328131185 cites W2945564879 @default.
- W4328131185 cites W2996729736 @default.
- W4328131185 cites W3001603296 @default.
- W4328131185 cites W3025082211 @default.
- W4328131185 cites W3036406116 @default.
- W4328131185 cites W3088531804 @default.
- W4328131185 cites W3118054665 @default.
- W4328131185 cites W3157837279 @default.
- W4328131185 cites W3181864632 @default.
- W4328131185 cites W3185156158 @default.
- W4328131185 cites W4211146858 @default.
- W4328131185 cites W4214611260 @default.
- W4328131185 cites W4226390647 @default.
- W4328131185 cites W4283716432 @default.
- W4328131185 doi "https://doi.org/10.21203/rs.3.rs-2655905/v1" @default.
- W4328131185 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36993733" @default.
- W4328131185 hasPublicationYear "2023" @default.
- W4328131185 type Work @default.
- W4328131185 citedByCount "0" @default.
- W4328131185 crossrefType "posted-content" @default.
- W4328131185 hasAuthorship W4328131185A5000623233 @default.
- W4328131185 hasAuthorship W4328131185A5003136757 @default.
- W4328131185 hasAuthorship W4328131185A5009492679 @default.
- W4328131185 hasAuthorship W4328131185A5013685119 @default.
- W4328131185 hasAuthorship W4328131185A5027611546 @default.
- W4328131185 hasBestOaLocation W43281311851 @default.
- W4328131185 hasConcept C126322002 @default.
- W4328131185 hasConcept C134018914 @default.
- W4328131185 hasConcept C168563851 @default.
- W4328131185 hasConcept C197934379 @default.
- W4328131185 hasConcept C203092338 @default.
- W4328131185 hasConcept C2777180221 @default.
- W4328131185 hasConcept C2777451236 @default.
- W4328131185 hasConcept C2779306644 @default.
- W4328131185 hasConcept C2781283889 @default.
- W4328131185 hasConcept C555293320 @default.
- W4328131185 hasConcept C71924100 @default.
- W4328131185 hasConcept C98274493 @default.
- W4328131185 hasConceptScore W4328131185C126322002 @default.
- W4328131185 hasConceptScore W4328131185C134018914 @default.
- W4328131185 hasConceptScore W4328131185C168563851 @default.
- W4328131185 hasConceptScore W4328131185C197934379 @default.
- W4328131185 hasConceptScore W4328131185C203092338 @default.
- W4328131185 hasConceptScore W4328131185C2777180221 @default.
- W4328131185 hasConceptScore W4328131185C2777451236 @default.
- W4328131185 hasConceptScore W4328131185C2779306644 @default.
- W4328131185 hasConceptScore W4328131185C2781283889 @default.
- W4328131185 hasConceptScore W4328131185C555293320 @default.
- W4328131185 hasConceptScore W4328131185C71924100 @default.
- W4328131185 hasConceptScore W4328131185C98274493 @default.
- W4328131185 hasLocation W43281311851 @default.
- W4328131185 hasLocation W43281311852 @default.
- W4328131185 hasLocation W43281311853 @default.
- W4328131185 hasOpenAccess W4328131185 @default.
- W4328131185 hasPrimaryLocation W43281311851 @default.
- W4328131185 hasRelatedWork W1983641721 @default.
- W4328131185 hasRelatedWork W1995945960 @default.
- W4328131185 hasRelatedWork W2026226896 @default.
- W4328131185 hasRelatedWork W2041678535 @default.
- W4328131185 hasRelatedWork W2066345847 @default.
- W4328131185 hasRelatedWork W2089387278 @default.
- W4328131185 hasRelatedWork W2092579885 @default.
- W4328131185 hasRelatedWork W2095179743 @default.
- W4328131185 hasRelatedWork W2130904138 @default.
- W4328131185 hasRelatedWork W4230655895 @default.
- W4328131185 isParatext "false" @default.
- W4328131185 isRetracted "false" @default.
- W4328131185 workType "article" @default.